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Ultra-high productivity continuous bioprocesses have been developed for production of various biologics 
including monoclonal antibodies, fusion proteins and bispecfic antibodies. This enables, for example, 2,000L 
disposable bioreactors to achieve comparable productivity as traditional 20,000L stainless bioreactors, and to 
significantly reduce manufacturing cost of goods. This process technology platform consists of continuous cell 
culture and continuous direct product capture, and is being scaled up and implemented for production of clinical 
materials. Several case studies, which achieved a cell culture productivity of 2-3 g/L/day, and a similar 
purification yield of the traditional purification process, will highlight advantages of this integrated continuous 
process platform in terms of productivity gains and speed to clinic. Scale up and implementation challenges will 
also be discussed. 
  
 
 
